Immune Thrombocytopenia Nomenclature, Consensus Reports, and Guidelines: What Are the Consequences for Daily Practice and Clinical Research?

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Michel, Marc ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYTOKINE RECEPTOR AGONIST; DANAZOL; DAPSONE; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; VINCA ALKALOID;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DISEASE COURSE; DRUG CHOICE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE THROMBOCYTOPENIA; IMMUNOPATHOLOGY; MEDICAL DECISION MAKING; NOMENCLATURE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLENECTOMY; STANDARDIZATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

BIOMEDICAL RESEARCH; CONSENSUS; HEALTH PLANNING GUIDELINES; HUMANS; PRACTICE GUIDELINES AS TOPIC; TERMINOLOGY AS TOPIC; THROMBOCYTOPENIA;

EID: 84877658411     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.008     Document Type: Article

References (19)

1. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guide developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
2. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br.J Haematol 2003, 120:574-596. British Committee for the Standards in Haematology (BCSH).
3. Godeau B., Porcher R., Fain O., et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura-results of a prospective multicenter phase 2 study. Blood 2008, 112:999-1004.
4. Zaja F., Baccarani M., Mazza P., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
5. Bussel J.B., Kuter D.J., George J.N., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006, 355:1672-1681.
6. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007, 357:2237-2247.
7. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
8. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
9. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
10. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
11. Sailer T., Lechner K., Panzer S., Kyrle P.A., Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006, 91:1041-1045.
12. Kühne T., Berchtold W., Michaels L.A., et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011, 96:1831-1837.
13. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.Lancet 2008, 371:395-403.
14. Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia (ITP): a preliminary report from the International Working Group on ITP (IWG on ITP). Blood. 2013, Jan 29 (Epub ahead of print).
15. Mazzucconi M.G., Fazi P., Bernasconi S., et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007, 109:1401-1407.
16. Cheng Y., Wong R.S., Soo Y.O., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003, 349:831-836.
17. Stasi R., Newland A., Thornton P., Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol 2010, 89:1185-1195.
18. Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104:2623-2634.
19. Rodeghiero F., Besalduch J., Michel M., Provan D., Grotzinger K., Thompson G. Treatment practices in adults with chronic immune thrombocytopenia-a European perspective. Eur J Haematol 2010, 84:160-168.